On January 2, AstraZeneca announced that the National Medical Products Administration has approved its drug Tagrisso (generic name: osimertinib mesylate tablets) for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) who have not experienced disease progression during or after platinum-containing chemoradiotherapy and have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations. It has also become the first and only targeted treatment option approved in China for stage III unresectable non-small cell lung cancer with EGFR mutations.